FR2928835A1 - DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. - Google Patents
DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. Download PDFInfo
- Publication number
- FR2928835A1 FR2928835A1 FR0801545A FR0801545A FR2928835A1 FR 2928835 A1 FR2928835 A1 FR 2928835A1 FR 0801545 A FR0801545 A FR 0801545A FR 0801545 A FR0801545 A FR 0801545A FR 2928835 A1 FR2928835 A1 FR 2928835A1
- Authority
- FR
- France
- Prior art keywords
- extract
- crocus sativus
- depigmenting
- kaempferol
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 244000124209 Crocus sativus Species 0.000 title claims abstract description 30
- 235000015655 Crocus sativus Nutrition 0.000 title claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 45
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims abstract description 40
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000008777 kaempferol Nutrition 0.000 claims abstract description 21
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 21
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims description 19
- 230000019612 pigmentation Effects 0.000 claims description 8
- 229930003935 flavonoid Natural products 0.000 claims description 5
- 235000017173 flavonoids Nutrition 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000035614 depigmentation Effects 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 31
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 210000002615 epidermis Anatomy 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 13
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 11
- 108060008724 Tyrosinase Proteins 0.000 description 11
- 208000012641 Pigmentation disease Diseases 0.000 description 9
- -1 fatty acid ester Chemical class 0.000 description 9
- 235000004237 Crocus Nutrition 0.000 description 8
- 241000596148 Crocus Species 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical class OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- 229960004705 kojic acid Drugs 0.000 description 7
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000007854 depigmenting agent Substances 0.000 description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 3
- 235000011957 flavonols Nutrition 0.000 description 3
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 3
- 229940093767 glabridin Drugs 0.000 description 3
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 3
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000003810 hyperpigmentation Effects 0.000 description 3
- 150000002556 kaempferol derivatives Chemical class 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- UFSKIYBOKFBSOA-MLYSRARTSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octadecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UFSKIYBOKFBSOA-MLYSRARTSA-N 0.000 description 2
- ORUDEUCNYHCHPB-OUUBHVDSSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-tetradecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ORUDEUCNYHCHPB-OUUBHVDSSA-N 0.000 description 2
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241001647091 Saxifraga granulata Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 239000008132 rose water Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 2
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DEKFZWMENCCOFU-LIKAHPKFSA-N 2-[(2r)-2-[(2r,3s,4r)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC[C@@H](OCCO)[C@H]1OC[C@@H](OCCO)[C@@H]1OCCO DEKFZWMENCCOFU-LIKAHPKFSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- WMJBVALTYVXGHW-UHFFFAOYSA-N 3,3-diphenylprop-2-enoic acid Chemical compound C=1C=CC=CC=1C(=CC(=O)O)C1=CC=CC=C1 WMJBVALTYVXGHW-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 241000865461 Mitracarpus Species 0.000 description 1
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- BOWQXVKOPFKONU-UHFFFAOYSA-N P(=O)(OCCCCCCCCCCCCCCCC)(O)O.C(CCCCCCCCCCCCCCC)(=O)OCCCCCCCCCCCCCCCC Chemical compound P(=O)(OCCCCCCCCCCCCCCCC)(O)O.C(CCCCCCCCCCCCCCC)(=O)OCCCCCCCCCCCCCCCC BOWQXVKOPFKONU-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- 244000147370 Sclerocarya caffra Species 0.000 description 1
- 235000001836 Sclerocarya caffra Nutrition 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020379 cucumber juice Nutrition 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 229940011399 escin Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- 208000031066 hyperpigmentation of the skin Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical class COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000002974 melatonin derivative Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- VTQCKDJHYPCDHH-UHFFFAOYSA-N octan-4-yl 2-methoxy-3-phenylprop-2-enoate Chemical compound CCCCC(CCC)OC(=O)C(OC)=CC1=CC=CC=C1 VTQCKDJHYPCDHH-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000009329 organic farming Methods 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
L'invention concerne une composition cosmétique et/ou dermatologique à base de kaempferol.La composition comprend un extrait de Crocus sativus, de préférence un extrait hydroalcoolique ou hydroglycolique de pétales de Crocus sativus, contenant du kaempferol.Application au traitement de dépigmentation de la peau.The invention relates to a cosmetic and / or dermatological composition based on kaempferol.The composition comprises an extract of Crocus sativus, preferably a hydroalcoholic or hydroglycolic extract of Crocus sativus petals, containing kaempferol.Application to depigmentation treatment of the skin .
Description
La présente invention concerne une nouvelle composition à base de kaempferol utilisable comme agent dépigmentant de l'épiderme, et plus particulièrement un extrait de Crocus sativus contenant du kaempferol, utilisable comme dépigmentant ou dans une composition dépigmentante. La dépigmentation de la peau peut être souhaitée dans diverses circonstances, soit pour un éclaircissement global de celle-ci, soit pour éliminer ou atténuer des taches provoquées par des troubles locaux de la pigmentation.. The present invention relates to a novel composition based on kaempferol that can be used as an agent for depigmenting the epidermis, and more particularly an extract of Crocus sativus containing kaempferol, which can be used as a depigmenting agent or in a depigmenting composition. Depigmentation of the skin may be desired under various circumstances, either for overall lightening of the skin, or to eliminate or reduce spots caused by local pigmentation disorders.
La peau comprend plusieurs couches intégrées, allant de la couche superficielle, l'épiderme (tissu épithéliE.l), jusqu'aux couches plus profondes, le derme et l'hypoderme (tissu conjonctif), et chacune possède des propriétés spécifiques permettant à l'ensemble de réagir et de s'adapter aux conditions de son environnement. La pigmentation de la peau résulte de la présence de mélanine dans l'épiderme et le derme. La mélanine est produite par les mélar.ocytes situés principalement dans la couche basale, en présence de la tyrosinase (ou monophénol mcno-oxygénase), une enzyme cupro-protéique qui catalyse la transformation de la tyrosine en dihydroxyphénylalanine (dopa) qui est ensuite transformée en dopaquinone, puis en dopachrome, pour aboutir à la mélanine suivant un mécanisme complexe. Cette biosynthèse, ou mélanogenèse, est un processus complexe qui est aujourd'hui relativement bien connu. Dans des conditions normales, la pigmentation de la peau est uniforme. Toutefois, on observe fréquemment l'apparition d'une hyperpigmentation, c'est-à-dire une pigmentation excessive localement, qui peut se manifester par des taches de rousseur, lentigo sénile, mélasme, des taches de vieillissement, une pigmentation due à une exposition excessive au soleil, une hyperpigmentation post-inflammatoire due à l'abrasion, des dermites, etc. L'hyperpigmentation de la peau peut être combattue au 35 moyen d'un composé susceptible de dégrader la mélanine, ou B1B42FR d'inhiber la biosynthèse de la mélanine, ou encore en utilisant un inhibiteur de tyrosinase qui bloque ou inhibe le mécanisme décrit ci-dessus. Ainsi, l'hydroquinone et certains de ses dérivés peuvent agir en inhibant la tyrosinase et en empêchant la Fixation de son substrat naturel, la tyros=_ne. Ainsi, le brevet EP-A-060.092 décrit l'utilisation d'un ester d'hydroquinone et d'acide gras, et le brevet US-A-4.692.261 décrit une composition dépigmentante contenant de l'hydroquinone, un détergent anionique et un stabilisant. On connaît également des associations à base d'hydroquinone, comme par exemple l'association d'hydroquinone et d'acide salicylique décrite dans le brevet FR-A-2.754.253. Cependant, l'hydroquinone présente l'inconvénient d'une forte toxicité entraînant des effets secondaires tels qu'une irritation de la peau. The skin has several integrated layers, ranging from the superficial layer, the epidermis (epithelial tissue), to the deeper layers, the dermis and the hypodermis (connective tissue), and each has specific properties allowing to react and adapt to the conditions of its environment. The pigmentation of the skin results from the presence of melanin in the epidermis and the dermis. Melanin is produced by melarocytes located mainly in the basal layer, in the presence of tyrosinase (or monophenol monooxygenase), a cuproprotein enzyme that catalyzes the transformation of tyrosine into dihydroxyphenylalanine (dopa) which is then transformed. in dopaquinone, then dopachrome, to achieve melanin following a complex mechanism. This biosynthesis, or melanogenesis, is a complex process that is today relatively well known. Under normal conditions, the pigmentation of the skin is uniform. However, hyperpigmentation is frequently observed, ie excessive pigmentation locally, which may manifest as freckles, senile lentigo, melasma, age spots, pigmentation due to excessive exposure to the sun, post-inflammatory hyperpigmentation due to abrasion, dermatitis, etc. Hyperpigmentation of the skin can be combated using a compound capable of degrading melanin, or B1B42FR inhibiting the biosynthesis of melanin, or using a tyrosinase inhibitor which blocks or inhibits the mechanism described above. above. Thus, hydroquinone and some of its derivatives can act by inhibiting tyrosinase and preventing the binding of its natural substrate, the tyrosine. Thus, EP-A-060 0 92 describes the use of a hydroquinone and fatty acid ester, and US Pat. No. 4,692,261 describes a depigmenting composition containing hydroquinone, anionic detergent and a stabilizer. Hydroquinone-based combinations are also known, such as, for example, the combination of hydroquinone and salicylic acid described in patent FR-A-2,754,253. However, hydroquinone has the disadvantage of a high toxicity causing side effects such as irritation of the skin.
D'autres substances dépigmentantes ont été proposées, et par exemple des dérivés de mélatonine comme dans le brevet FR 2.751.535, des dérivés d'acide salicylique comme dans le brevet FR 2.732.594, des extraits de plantes du genre Mitracarpus comme dans le brevet FR 2.751.874, ou encore des esters d'acide kojique présentant une action éclaircissante sur la peau, comme décrit dans le brevet FR 2.460.131. Cependant, l'acide kojique est instable en solution et son utilisation en dermatologie est délicate. De plus, les sels et esters d'acide kojique présentent souvent un effet allergisant. Des extraits de Glycyrrhiza contenant des substances telles que la glabridine, ont aussi été utilisés pour inhiber la production de mélanine par les cellules du derme en bloquant la tyrosinase mise en œuvre dans sa synthèse, et des compositions dépigmentantes contenant de la glabridine ont été proposées comme dans le brevet FR 2.822.067. Malgré les méthodes et compositions existantes, il existe un besoin accru dans le domaine cosmétologique de mettre au point des méthodes alternatives de traitement de la pigmen- tation de la peau et de l'hyperpigmentation, et par conséquent d'identifier des composés possédant des propriétés dépign'en- 3 tantes, et notamment des compositions topiques à base d'ex-traits végétaux susceptibles d'avoir des effets dépigmer..tants. Le kaempferol est un flavonoïde dérivé du flavonol, représenté par la formule générale ci-après. Other depigmenting substances have been proposed, and for example melatonin derivatives as in patent FR 2,751,535, salicylic acid derivatives, such as in patent FR 2,732,594, extracts of plants of the genus Mitracarpus, as in the US Pat. patent FR 2 751 874, or kojic acid esters having a lightening action on the skin, as described in patent FR 2,460,131. However, kojic acid is unstable in solution and its use in dermatology is delicate. In addition, the salts and esters of kojic acid often have an allergenic effect. Glycyrrhiza extracts containing substances such as glabridin have also been used to inhibit the production of melanin by dermal cells by blocking the tyrosinase used in its synthesis, and depigmenting compositions containing glabridin have been proposed as in FR 2,822,067. Despite the existing methods and compositions, there is an increased need in cosmetology to develop alternative methods for the treatment of skin pigmentation and hyperpigmentation, and therefore to identify compounds with properties in particular, topical compositions based on ex-plant traits which may have depigmenting effects. Kaempferol is a flavonoid derived from flavonol, represented by the general formula below.
HO O Le kaempferol a été isolé à partir de plantes telles que le thé, le broccoli et plusieurs fleurs du genre acacia qui lui doivent leur couleur jaune. Il se présente à température ambiante sous forme de solide cristallin de couleur jaune, peu soluble dans l'eau, de point de fusion F = 276-278°C. Diverses propriétés du kaempferol ont été décrites, en particulier des propriétés anti-oxydantes, ainsi que des propriétés anti-inflammatoires par inhibition de la formation d'oxyde nitrique NO (M. Hamalainen et al., "Mediators of inflammation" Hindawi Publ. Vol 2007, ID45673). I. Kubo et al., Bioorg. Med. Chem., 8(7):1749-1755 (2000) ont montré que certains flavonols et le kaempferol possèdent aussi une activité inhibitrice de la tyrosinase, provenant de leur aptitude à chélater le cuivre de l'enzyme tyrosinase. HO O Kaempferol was isolated from plants such as tea, broccoli and several acacia flowers that owe their yellow color. It is at room temperature in the form of a crystalline solid of yellow color, slightly soluble in water, melting point F = 276-278 ° C. Various properties of kaempferol have been described, in particular antioxidant properties, as well as anti-inflammatory properties by inhibiting the formation of nitric oxide NO (M. Hamalainen et al., "Mediators of inflammation" Hindawi Publ. 2007, ID45673). I. Kubo et al., Bioorg. Med. Chem., 8 (7): 1749-1755 (2000) have shown that certain flavonols and kaempferol also possess a tyrosinase inhibitory activity, derived from their ability to chelate the enzyme tyrosinase.
Toutefois, la coloration jaune que le kaempferol donne aux compositions qui le contiennent empêche son utilisation dans des compositions cosmétiques ou dermatologiques destinées à la dépigmentation de la peau. De plus, le kaempferol est très peu soluble dans l'eau, ce qui limite encore son utilisation dans des compositions cosmétiques. Des études ont montré que les pétales de fleurs du genre Crocus, et notamment l'espèce C. sativus, contiennent du kaempferol. Les crocus, dont plusieurs espèces sont cultivées comme fleurs ornementales à floraison automnale, se rencon-trent dans quelques régions d'Asie et d'Europe méridionale de l'Iran à l'Espagne. L'espèce Crocus sativus est connue pour la production de safran obtenu à partir des stigmates séchés de la fleur. Les études effectuées par la demanderesse ont montré de manière inattendue que des extraits de Crocus sat-_vus contenant des dérivés du kaempferol présentent une bonne activité dépigmentante dépourvue d'effets secondaires, sans entraîner de coloration de la composition, et peuvent donc être utilisés efficacement en cosmétologie et en dermatologie pour la dépigmentation de la peau. De p=_us, les dérivés de kaempferol présents dans l'extrait, plus particulièrement les glycosides de kaempferol, sont solubles dans l'eau, tout en conservant un excellent effet dépigmentant. Dans ce qui suit, le terme "kaempferol" est utilisé pour désigner les dérivés à action dépigmentante ou éclaircissante, en particulier les glycosides. La présente invention a donc pour objet une ncuvelle composition comprenant un extrait de Crocus sativus contenant du kaempferol, plus particulièrement un dérivé de kaempferol, utilisable à titre d'agent dépigmentant en cosmétologie et en dermatologie. L'invention a aussi pour objet une nouvelle utilisation d'un extrait de Crocus sativus contenant du kaempferol pour la préparation d'une composition cosmétique et/ou dermatologique destinée à inhiber la pigmentation de la peau. However, the yellow color that kaempferol gives to the compositions which contain it prevents its use in cosmetic or dermatological compositions intended for the depigmentation of the skin. In addition, kaempferol is very slightly soluble in water, which further limits its use in cosmetic compositions. Studies have shown that flower petals of the genus Crocus, including the species C. sativus, contain kaempferol. Crocuses, many of which are grown as fall flowering ornamental flowers, are found in parts of Asia and southern Europe from Iran to Spain. The species Crocus sativus is known for the production of saffron obtained from the dried stigmas of the flower. The studies carried out by the applicant have unexpectedly shown that Crocus extracts containing kaempferol derivatives exhibit good depigmenting activity without side effects, without causing coloration of the composition, and can therefore be used effectively in cosmetology and dermatology for depigmentation of the skin. From this, the kaempferol derivatives present in the extract, more particularly the kaempferol glycosides, are soluble in water, while maintaining an excellent depigmenting effect. In what follows, the term "kaempferol" is used to designate derivatives with depigmenting or lightening action, in particular glycosides. The present invention therefore relates to a novel composition comprising a Crocus sativus extract containing kaempferol, more particularly a kaempferol derivative, used as a depigmenting agent in cosmetology and dermatology. The subject of the invention is also a novel use of an extract of Crocus sativus containing kaempferol for the preparation of a cosmetic and / or dermatological composition intended to inhibit the pigmentation of the skin.
L'invention a encore pour objet l'utilisation c'un extrait de Crocus sativus à titre d'agent dépigmentant L'invention a encore pour objet une nouvelle composition topique spéciaement adaptée à une telle utilisation, comprenant un extrait de Crocus sativus en une concentration adaptée à l'effet recherché. L'invention a encore pour objet une méthode de dépigmentation de la peau, consistant à appliquer sur les zones exposées une composition comprenant un extrait de Crocus sativus contenant du kaempferol. The subject of the invention is also the use of an extract of Crocus sativus as a depigmenting agent. The subject of the invention is also a new topical composition specially adapted for such use, comprising an extract of Crocus sativus in a concentration. adapted to the desired effect. The subject of the invention is also a method for depigmenting the skin, comprising applying to the exposed areas a composition comprising an extract of Crocus sativus containing kaempferol.
Suivant l.a présente invention, l'extrait de Crocus sativus est obtenu de préférence à partir de pétales de fleurs blanches. La littérature dans le domaine cosmétique évoque selon les cas des propriétés éclaircissantes ou des propriétés dépigmentantes pour la peau. Dans le cadre de la présente invention, les propriétés dépigmentantes comprennent, outre les propriétés permettant de lutter contre l'hyperpigmentation, également ces propriétés éclaircissantes. According to the present invention, the Crocus sativus extract is preferably obtained from white flower petals. The literature in the cosmetic field evokes, depending on the case, lightening properties or depigmenting properties for the skin. In the context of the present invention, the depigmenting properties comprise, in addition to the properties making it possible to fight against hyperpigmentation, also these lightening properties.
La composition de l'invention contient un extrait de Crocus sativus, et il s'agit de préférence d'un extrait de pétales de C=ocus sativus, et plus particulièrement d'un extrait hydroalcoolique ou, de préférence, hydroglycolique. Un extrait hydroalcoolique se présente généralement sous la forme d'un liquide se caractérisant par : - matières sèches environ 4% - densité 0,892 - T.A. env. 70 % vol. - indice de réfraction (à 22°C) 1,368 - teneur en flavonoïdes 1,88% - pH : 6,0 L'extrait suivant l'invention peut représenter entre 0,1 à 20% en poids par rapport au poids total de la composition, de préférence entre 2 et 10 La teneur en flavonoïdes est exprimée en pourcentage de la matière sèche. L'extrait hydroalcoolique utilisé dans l'invention présente l'avantage d'avoir une teneur relativement élevée en flavonoïdes, principalement flavonols et flavanols, et une bonne aptitude à la conservation dans le temps, dans des conditions normales de température et d'humidité, de préférence à l'abri. de la lumière. Il contient en particulier du glycoside de kaempferol. Il peut être préparé à partir de fleurs fraîches finement divisées, par macération sous agitation pendant plusieurs jours dans de l'alcool éthylique, à raison d'environ 100 g de fleurs pour 1 d'alcool. The composition of the invention contains an extract of Crocus sativus, and it is preferably an extract of petals of C = ocus sativus, and more particularly of a hydroalcoholic or, preferably, glycolic acid extract. A hydroalcoholic extract is generally in the form of a liquid characterized by: - dry matter about 4% - density 0.892 - T.A. 70% vol. refractive index (at 22 ° C.) 1.368 - flavonoid content 1.88% - pH: 6.0 The extract according to the invention can represent between 0.1% and 20% by weight relative to the total weight of the composition, preferably between 2 and 10 The content of flavonoids is expressed as a percentage of the dry matter. The hydroalcoholic extract used in the invention has the advantage of having a relatively high content of flavonoids, mainly flavonols and flavanols, and a good aptitude for storage over time, under normal conditions of temperature and humidity, preferably in the shelter. light. It contains in particular kaempferol glycoside. It can be prepared from finely divided fresh flowers by maceration with stirring for several days in ethyl alcohol, at a rate of about 100 g of flowers to 1 alcohol.
L'extrait ainsi préparé peut être utilisé tel quel ou être décoloré au charbon actif. Suivant l'invention, il est avantageux de compléter l'action éclaircissante et dépigmentante du kaempferol en ajoutant à la composition des substances exerçant un effet dépigmentant telles que l'arbutine, la glabridine, la scutellaire, 1a vitamine C (acide ascorbique) ou l'acide kojique, ainsi que leurs dérivés tels que sels et esters, ou un anti-pigmentant tel qu'un extrait de saxifrage qui réduit la mélanine. Des agents de protection contre les rayons ultraviolets peuvent aussi être avantageusement incorporés dans les compositions, et par exemple des filtres solaires UV-A et UV-B hydrophiles ou lipophiles, choisis parmi la benzophénone ot. un dérivé de benzophénone tel que la 2-hydroxy-4-méthoxybenzophénone (Eusolex 4360), ou un ester d'ac_de cinnamique et plus particulièrement le méthoxycinnamate d'octyle (Eusolex 2292), le méthoxycinnamate d'éthyl-2-hexyle (Parsol MCX ), ou encore un cyano-(3,3-diphénylacrylate tel que l'octo- crylène (Eusolex OCR) et des dérivés du dibenzoylméthane tels que le 4-isopropyl dibenzoylméthane (Eusolex 8020), le tbutyl-méthoxy dibenzoylméthane (Parsol 1789 ), et le 4-méthoxy-dibenzoylméthane. On peut aussi utiliser des pigments formant écran anti-ultraviolet, comme par exemple le dioxyde de titane, l'oxyde de zinc, l'oxyde de zirconium ou encore l'oxyde d'aluminium. Les compositions conformes à la présente invention peuvent être présentées sous les formes classiquement utilisées pour une application topique, c'est-à-dire sous forme de solut__on aqueuse ou hydroalcoolique, de gel, lotion, émulsion (en particulier crème ou lait), bâtonnet pour les lèvres, masque, pommade, sérum, patchs transdermiques, nanocapsules ou liposomes contenant des excipients et supports usuels compatioles et pharmaceutiquement acceptables. Elles peuvent aussi se présenter sous forme de lingettes imbib=es d'une solution contenant l'extrait de pétales de Crocus sativus. Ces formes d'administration par voie topique sont préparées par les techniques connues, et par exemple, dans le cas d'une crème, par dispersion d'une phase grasse dans une phase aqueuse pour obtenir une émulsion huile dans eau, ou inversement pour préparer une émulsion eau dans huile. Dans le cas de crèmes, on préfère utiliser des émulsions à structure lamellaire contenant peu de produits éthoxylés ou n'en contenant pas du tout. The extract thus prepared can be used as it is or decolorized with activated charcoal. According to the invention, it is advantageous to supplement the lightening and depigmenting action of kaempferol by adding to the composition substances having a depigmenting effect such as arbutin, glabridin, skullcap, vitamin C (ascorbic acid) or kojic acid, as well as their derivatives such as salts and esters, or an anti-pigmenting agent such as a saxifrage extract which reduces melanin. Ultraviolet protection agents may also advantageously be incorporated in the compositions, and for example hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from benzophenone oto. a benzophenone derivative such as 2-hydroxy-4-methoxybenzophenone (Eusolex 4360), or a cinnamic acid ester and more particularly octyl methoxycinnamate (Eusolex 2292), ethyl-2-hexyl methoxycinnamate (Parsol MCX), or a cyano- (3,3-diphenylacrylate such as octo-crylene (Eusolex OCR) and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane (Eusolex 8020), tbutyl-methoxy dibenzoylmethane (Parsol 1789 ), and 4-methoxy-dibenzoylmethane It is also possible to use anti-ultraviolet screen pigments such as, for example, titanium dioxide, zinc oxide, zirconium oxide or aluminum oxide. The compositions according to the present invention may be presented in the forms conventionally used for topical application, that is to say in the form of aqueous or aqueous-alcoholic solution, gel, lotion, emulsion (in particular cream or milk), stick for the lips, my squeegee, ointment, serum, transdermal patches, nanocapsules or liposomes containing conventional and compatible pharmaceutically acceptable excipients and carriers. They may also be in the form of wipes impregnated with a solution containing the petal extract of Crocus sativus. These forms of topical administration are prepared by the known techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion. In the case of creams, it is preferred to use lamellar structure emulsions containing little or no ethoxylated products.
Les compositions topiques selon l'invention peuvent comprendre des excipients appropriés pour une administration topique externe, en particulier des excipients acceptables sur le plan dermatologique et cosmétologique. Ces excipients appropriés pour la formulation sont bien connus de l'homme du métier et comprennent en particulier des agents de pénétration tels que l'éthoxydiphénol, le phytantriol, l'octyl dodécanol et l'escine ; les épaississants tels que les gommes naturelles et les polymères de synthèse ; les émollients et les tensioactifs tels que l'octanoate de cétéaryle, le myristate d'isopropyle, l'isononanoate de cétéaryle, la diméthicone, la cyclométhicone, le 3-diisostéarate de polyglycéryle, le polyisobutène hydrogéné, l'alcool cétylique, le palmitate cétylique, le phosphate cétylique, des triglycérides d'acide caprique et caprylique ; les émulsionnants tels que des esters de sorbitane, des dérivés d'acide stéarique ou palmitique, des sucro-esters cu glucolipides du type myristyl glucoside ou stéaryl glucoside ; les conservateurs tels que le phénoxyéthanol, le parahydroxybenzoate de méthyle (méthylparaben), le parahydroxybenzoate d'éthyle (éthylparaben), le parahydroxy- benzoate de propyle (propylparaben) et le Phenonip assoc__ant du phénoxyéthanol et des parahydroxybenzoates de méthyle, éthyle, butyle et isobutyle ; une association à effet antimicrobien d'un lipoaminoacide, d'un acide gras hydroxylé de 8 à 12 atomes de carbone et d'un alkyléther de glycérine; les colorants ; les parfums ; etc. The topical compositions according to the invention may comprise excipients suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients. These excipients suitable for the formulation are well known to those skilled in the art and include in particular penetration agents such as ethoxydiphenol, phytantriol, octyl dodecanol and escin; thickeners such as natural gums and synthetic polymers; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, hydrogenated polyisobutene, cetyl alcohol, cetyl palmitate cetyl phosphate, triglycerides of capric and caprylic acid; emulsifiers such as sorbitan esters, stearic or palmitic acid derivatives, sucro-esters or glucolipids of the myristyl glucoside or stearyl glucoside type; preservatives such as phenoxyethanol, methyl parahydroxybenzoate (methylparaben), ethyl parahydroxybenzoate (ethylparaben), propylparaben parahydroxybenzoate (propylparaben) and Phenonip associated with phenoxyethanol and methyl, ethyl, butyl and isobutyl parahydroxybenzoates ; an antimicrobial combination of a lipoamino acid, a hydroxylated fatty acid of 8 to 12 carbon atoms and a glycerin alkyl ether; dyes; the perfumes ; etc.
Des exemples non limitatifs de compositions conformes à la présente invention sont donnés ci-après. Sauf indication contraire, les pourcentages et parties sont indiqués en poids. Non-limiting examples of compositions according to the present invention are given below. Unless otherwise indicated, percentages and parts are by weight.
Exemple 1 Evaluation de l'effet dépigmentant L'effet dépigmentant a été évalué in vitro sur des épidermes reconstitués (Skineth.ic ) en coculture avec des mélanocytes humains, après contrôle de la cytotoxicité, comme indiqué ci-après. Example 1 Evaluation of the Depigmenting Effect The depigmenting effect was evaluated in vitro on reconstituted epidermis (Skineth.ic) in coculture with human melanocytes, after control of the cytotoxicity, as indicated below.
Des kératinocytes d'origine humaine ont été cultivés dans un milieu défini MCDB 153 modifié) et supplémentés. Les cellules sont cultivées pendant 10 jours à l'interface air/liquide, le milieu de culture étant changé tous les deux jours. Keratinocytes of human origin were cultured in a defined medium MCDB 153 modified) and supplemented. The cells are cultured for 10 days at the air / liquid interface, the culture medium being changed every two days.
Les épidermes ainsi formés sur des filtres en polycarbonate (0,63 cm2) ont été mis en coculture avec des mélanocytes humains. L'étude a été réalisée entre les 11' et 17eme jours de culture. The epidermis thus formed on polycarbonate filters (0.63 cm 2) were co-cultured with human melanocytes. The study was carried out between the 11th and 17th days of culture.
Etude de la cytotoxicité L'étude a été réalisée en triplicate après 24H de contact avec les épidermes reconstitués (10 pl par cm2) . Le lot n° 1 est constitué par les épidermes témoins ne recevant aucun produit (témoins négatifs. Le lot n° 2 est constitué par les épidermes traités par l'extrait de Crocus sativus suivant l'invention. Le lot n° 3 est constitué par les épidermes témoins positifs recevant de l'acide kojique (2%) à titre de produit dépigmentant de comparaison. L'évaluation de la viabilité cellulaire a été faite par examen histologique. Les épidermes fixés dans une solution de formaldéhyde à 10% ont été inclus dans des blocs de paraffine et des coupes verticales de 4 pm d'épaisseur ont été colorées à l'hématoxyline/éosine (HES) puis photographiées sous microscope optique. Cytotoxicity study The study was performed in triplicate after 24 hours of contact with the reconstituted epidermis (10 μl per cm 2). Batch No. 1 consists of the control epidermis receiving no product (negative controls) Lot 2 consists of the epidermis treated with the Crocus sativus extract according to the invention. positive control epidermas receiving kojic acid (2%) as a comparative depigmenting product The evaluation of cell viability was made by histological examination The epidermis fixed in a 10% formaldehyde solution were included in paraffin blocks and vertical sections 4 μm thick were stained with hematoxylin / eosin (HES) and then photographed under an optical microscope.
On constate que les images histologiques, après coloration HES des épidermes traités par l'extrait de Crocus sat__vus de l'invention, sont similaires à celles des épidermes témoins. It is found that the histological images, after HES staining of the epidermis treated with the Crocus extract of the invention, are similar to those of the control epidermis.
Ces résultats montrent que l'extrait de Crocus sativus selon l'invention ne présente aucune activité cytotoxique vis-à-vis des cellules endothéliales de l'épiderme, aux concentrations testées (0,072 %). These results show that the Crocus sativus extract according to the invention exhibits no cytotoxic activity with respect to the endothelial cells of the epidermis, at the concentrations tested (0.072%).
Evaluation de l'effet dépigmentant L'évaluation de l'activité de l'extrait de Crocus sativus de l'invention sur la pigmentation cutanée a été faite par dosage de la mélanine et de la tyrosinase. Cette activité sur la pigmentation a été démontrée par • l'évaluation de l'activité de la tyrosinase • l'évaluation de la synthèse de la mélanine (étude qualitative de la mélanine intracellulaire par spectrométrie à 475 nm) Trois lots (témoin négatif, invention, comparaison) ont été préparés de la même manière que ci-dessus. Les épidermes 20 reconstitués sont les mêmes que ci-dessus. L'évaluation de la synthèse de la mélanine intra- cellulaire (étude qualitative) a été effectuée comme indiqué ci-dessus par spectrométrie à 475 nm après mise en suspension des cellules de peau humaine puis dissolution dans NaOH 1N et 25 du diméthyl sulfoxyde pendant 30 minutes. Les résultats sont regroupés dans le tableau ci-après. Absorbance (4 75 nrr.) % Témoin négatif 0,145 0,01 - Témoin positif (acide 0,080 0,02 -45 kojique) Extrait de Crocus 0,129 0,05 -11 sativus Ces résultats montrent que la composition de l'invention, à base d'extrait de Crocus sativus entraîne une diminution significative du taux de mélanine. Cette diminution est ici plus faible que le témoin à l'acide kojique mais elle est significative dès la dose testée de 0,07 %. Evaluation of the Depigmenting Effect The evaluation of the activity of the Crocus sativus extract of the invention on cutaneous pigmentation was made by assaying melanin and tyrosinase. This activity on pigmentation was demonstrated by • evaluation of tyrosinase activity • evaluation of melanin synthesis (qualitative study of intracellular melanin by spectrometry at 475 nm) Three lots (negative control, invention comparison) were prepared in the same manner as above. The reconstituted epidermis is the same as above. Evaluation of intracellular melanin synthesis (qualitative study) was performed as indicated above by spectrometry at 475 nm after suspending human skin cells and then dissolving in 1 N NaOH and dimethyl sulfoxide for 30 minutes. minutes. The results are summarized in the table below. Absorbance (4 75 nrr.)% Negative control 0.145 0.01 - Positive control (Acid 0.080 0.02 -45 kojic) Crocus extract 0.129 0.05 -11 sativus These results show that the composition of the invention, based on extract of Crocus sativus causes a significant decrease in melanin levels. This decrease is lower here than the control with kojic acid but it is significant from the tested dose of 0.07%.
Evaluation de l'activité de la tyrosinase A la fin de la période d'incubation, le milieu de culture a été prélevé, puis les épidermes ont été rincés avec du PBS et mis en contact du Triton X-100 (Sigma, France) à 1% puis incubés pendant 10 minutes. La réaction enzymatique a été initiée par l'addition de L-dopamine (Sigma, France) à 10 mM dans du PBS dépourvu de Cal+ et de Mg2+. Après 1 heure d'incubation à 37°C à l'abri de la lumiere, l'activité de la tyrosinase a été évaluée par la mesure de l'absorption à 475 nm au moyen d'un spectrophotomètre. Les résultats sont regroupés dans le tableau ci-après. Absorbance (475 nm) % Témoin négatif 0,215 0,02 - Témoin positif (acide 0,132 0,01 -38 kojique) Extrait de Crocus 0,185 0,01 -14 sativus Ces résultats montrent que l'extrait de Crocus sat=_vus entraîne une diminution significative de l'activité de la tyrosinase, bien que moins importante que celle de l'acide kojique. Evaluation of the activity of tyrosinase At the end of the incubation period, the culture medium was removed, then the epidermis was rinsed with PBS and brought into contact with Triton X-100 (Sigma, France). 1% and then incubated for 10 minutes. The enzymatic reaction was initiated by the addition of L-dopamine (Sigma, France) to 10 mM in PBS devoid of Cal + and Mg 2+. After 1 hour of incubation at 37 ° C in the dark, the tyrosinase activity was evaluated by measuring the absorption at 475 nm using a spectrophotometer. The results are summarized in the table below. Absorbance (475 nm)% Negative Control 0.215 0.02 - Positive Control (Acid 0.132 0.01 -38 kojic) Crocus Extract 0.185 0.01 -14 sativus These results show that the Crocus extract exhibited decreased significant activity of tyrosinase, although less important than that of kojic acid.
L'activité dépigmentante ainsi démontrée de l'extrait de Crocus sativus de l'invention montre que cet extrait peut être avantageusement utilisé dans des compositions cosmétiques éclaircissantes et dépigmentantes, à la place d'agents dépigmentants tels que l'acide kojique dont les inconvénients connus limitent l'utilisation. En raison de sa parfaite innocuité, l'extrait de Crocus sativus de l'invention peut donc être utilisé dans des compositions cosmétiques et dermatologiques dépigmentantes. The depigmenting activity thus demonstrated of the Crocus sativus extract of the invention shows that this extract can be advantageously used in lightening and depigmenting cosmetic compositions, in the place of depigmenting agents such as kojic acid whose known disadvantages limit the use. Because of its perfect safety, the Crocus sativus extract of the invention can therefore be used in depigmenting cosmetic and dermatological compositions.
De plus, les essais effectués ont montré que les compositions cosmétiques telles que celles décrites dans les exemples ci-après ne présentent pas de coloration indésirable liée à la présence de kaempferol. In addition, the tests carried out have shown that the cosmetic compositions such as those described in the examples below do not exhibit an undesirable coloration related to the presence of kaempferol.
Exemple 2 Préparation d'un extrait de Crocus sativus. 100 g de fleurs fraîches (pétales) finement divisées sont extraits avec 1 1 d'alcool éthylique bio à 70% (vol) par macération sous agitation pendant 7 jours. L'alcool éthylique Io bio est obtenu par fermentation naturelle de grains ou de fruits cultivés en agriculture biologique et sans add=_tif après distillation. Après extraction, le produit est passé et le résidu exprimé par pression ou centrifugation suivant les méthodes 15 classiques. Les deux liqueurs ainsi obtenues sont jointes et la quantité est ajustée à 1 1 avec de l'eau et de l'alcool éthylique à 70o vol. jusqu'à obtenir le titre alcoolique voulu. 20 On obtient ainsi un extrait liquide de couleur b=rune rougeâtre qui peut être utilisé tel quel ou être décoloré par addition de charbon actif. Example 2 Preparation of an extract of Crocus sativus. 100 g of fresh flowers (petals) finely divided are extracted with 1 1 of 70% organic ethyl alcohol (vol) by maceration with stirring for 7 days. Organic ethyl alcohol is obtained by natural fermentation of grains or fruits grown in organic farming and without additives after distillation. After extraction, the product is passed and the residue is expressed by pressure or centrifugation according to conventional methods. The two liquors thus obtained are joined and the amount is adjusted to 1 with water and ethyl alcohol at 70 ° vol. until you obtain the desired alcoholic strength. This gives a liquid extract of color b = reddish rune which can be used as it is or be decolorized by the addition of activated charcoal.
Exemple 3 On prépare une lotion dépigmentante comprenant un extrait 25 de Crocus sat=_vus obtenu comme indiqué dans l'Exemple 2, en mélangeant les composants ci-dessous, dans l'ordre indicué. Eau distillée de lotus 10,0 Eau déminéralisée q.s.p. 100,0 Alcool éthylique 96% 20,0 30 Jus de concombre 10,0 Extrait de Crocus sativus 10,0 Sulfate d'ascorbyle 1,0 Eau de rose bulgare 10,0 12 Cette lotion aqueuse peut être appliquée directement sur la peau, de préférence deux fois par jour, pour procurer un effet dépigmentant qui est observé dans la plupart des cas dès la 2ème à 4ème semaine de traitement. Example 3 A depigmenting lotion comprising a Crocus extract obtained as described in Example 2 was prepared by mixing the components below in the order indicated. Lotus distilled water 10.0 Demineralized water q.s. 100.0 Ethyl alcohol 96% 20.0 30 Cucumber juice 10.0 Crocus sativus extract 10.0 Ascorbyl sulfate 1.0 Bulgarian rose water 10.0 12 This aqueous lotion can be applied directly to the skin, preferably twice daily, to provide a depigmenting effect which is observed in most cases from the 2nd to 4th week of treatment.
Exemple 4 On prépare une essence éclaircissante au moyen des trois phases A, B et: C, dont la composition est donnée ci-dessous. Les phases A et C sont préparées à température ambiante tandis que la phase B est préparée en chauffant jusqu'à obtenir une solution transparente. Phase A Eau déminéralisée q.s.p. 100,00 EDTA trisodique 0,10 Benzophénone 5 0,05 Alcool éthylique 96% 10,00 Acide levulinique 0,50 Caprylyl glycine 0,30 Butylène glycol 5,00 Gomme xanthane 0,34 Ascorbyl phosphate de magnésium 0,40 Phase B Eau déminéralisée q.s.p. 10,00 Butylène glycol 3,00 Glycérine 9,00 PEG 60 huile de ricin hydrogénée 0,20 Di-isostéarate de polyglycéryle-2 0,10 Tocophérol 0,10 Beurre de Karité 0,05 Potasse 0,05 Phase C Extrait de saxifrage 0,50 Extrait de scutellaire 1,C0 Extrait de Crocus sativus 2,00 Eau de rose concentrée 5,00 La phase une fois homogénéisée, est ajoutée à la phase B, le mélange est maintenu sous agitation jusqu'à obtenir un mélange homogène, puis la phase A est ajoutée sous agitation. EXAMPLE 4 A lightening essence is prepared by means of the three phases A, B and C, the composition of which is given below. Phases A and C are prepared at room temperature while phase B is prepared by heating until a clear solution is obtained. Phase A Demineralized water q.s. 100.00 Trisodium EDTA 0.10 Benzophenone 5 0.05 Ethyl alcohol 96% 10.00 Levulinic acid 0.50 Caprylyl glycine 0.30 Butylene glycol 5.00 Xanthan gum 0.34 Ascorbyl magnesium phosphate 0.40 Phase B Water demineralized qs 10.00 Butylene glycol 3.00 Glycerin 9.00 PEG 60 hydrogenated castor oil 0.20 Di-polyglyceryl-2-isostearate 0.10 Tocopherol 0.10 Shea butter 0.05 Potash 0.05 Phase C Extract of saxifrage 0.50 Skullcap extract 1, C0 Crocus sativus extract 2.00 Rose water concentrate 5.00 The homogenized phase is added to phase B, the mixture is stirred until a homogeneous mixture is obtained, then phase A is added with stirring.
Exemple 5 On prépare une crème dépigmentante en mélangeant les quatre phases dont les compositions sont données ci-dessous. Phase A Eau déminéralisée q.s.p. 100,00 Acide phytique 0,10 Acide déhydroacétique 0, 10 Alcool benzylique 0,60 Carboxy vinyl polymère 0,10 Butylène glycol 3,00 Phase B Myristyl glucoside 1,50 Stéaryl glucoside 2,50 Alcool béhénylique 1,20 Huile de Marula 3,00 Triglycéride caprique / caprylique 3,00 Phase C Hydroxyde de potassium 0,03 Eau déminéralisée 3,00 Phase D Arbutine 2,00 Extrait de Crocus sativus 2,00 Ascorbyl sucrose 0,50 Alcool étylique 96% 10,00 Isoprène glycol 5,00 Les composants de la phase A sont mélangés à 70°C env:_ron puis on y ajoute la phase B sous agitation à température ambiante, et le mélange, après homogénéisation est additionné avec la phase C à 60°C. On ajoute ensuite la phase C après l'avoir soigneusement mélangée. EXAMPLE 5 A depigmenting cream is prepared by mixing the four phases, the compositions of which are given below. Phase A Demineralized water q.s. 100.00 Phytic acid 0.10 Dehydroacetic acid 0.10 Benzyl alcohol 0.60 Carboxy vinyl polymer 0.10 Butylene glycol 3.00 Phase B Myristyl glucoside 1.50 Stearyl glucoside 2.50 Behenyl alcohol 1.20 Marula oil 3 , 00 Capric / Caprylic Triglyceride 3.00 Phase C Potassium Hydroxide 0.03 Demineralized Water 3.00 Phase D Arbutin 2.00 Crocus sativus Extract 2.00 Ascorbyl Sucrose 0.50 Ethanol 96% 10.00 Isoprene Glycol 5 The components of phase A are mixed at 70 ° C. and then phase B is added with stirring at room temperature, and the mixture, after homogenization, is added with phase C at 60 ° C. Phase C is then added after careful mixing.
Exemple 6 On prépare une crème éclaircissante en mélangeant les 6 phases dont les compositions sont décrites ci-après. Phase A Perhydroqualène 5,00 Triglycéride caprique / caprylique 4,00 Huile de coprah hydrogénée 3,00 Alcool cétostéarylique 0,70 Huile de Jojoba 1,50 Huile de Macadamia 1,00 PEG 20 Stéarate de sorbitane 3,50 Stéarate de sorbitane 2,50 Diméthicone 0,75 Palmitate d'ascorbyle 0,15 Phase B Eau déminéralisée q.s p. 100,00 Acide déhydroacétique 0,15 Alcool benzylique 0,60 EDTA trisodique 0,10 Butylène glycol 5,00 Phase C Carbopol 0,12 Eau déminéralisée 10,00 Phase D Hydroxyde de potassium 0,05 Eau déminéralisée 3,00 15 Phase E Polyphéno.Ls de cacao 0,10 Extrait de Crocus sativus 5,00 Eau déminéralisée 5,00 Phase F Parfum 0,15 Les composants de la phase A sont mélangés à EO°C environ, et on y ajoute la phase B dont les composants sont mélangés à 75°C, la phase C à 70°C, la phase D à 60°C, puis la l0 phase E à 40°C, et enfin on ajoute les parfums à 35°C environ, pour obtenir une crème éclaircissante. Example 6 A lightening cream is prepared by mixing the 6 phases, the compositions of which are described below. Phase A Perhydroqualene 5.00 Capric / caprylic triglyceride 4.00 Hydrogenated coconut oil 3.00 Cetostearyl alcohol 0.70 Jojoba oil 1.50 Macadamia oil 1.00 PEG 20 Sorbitan stearate 3.50 Sorbitan stearate 2, Dimethicone 0.75 Ascorbyl palmitate 0.15 Phase B Demineralized water qs p. 100.00 Dehydroacetic acid 0.15 Benzyl alcohol 0.60 Trisodium EDTA 0.10 Butylene glycol 5.00 Phase C Carbopol 0.12 Demineralized water 10.00 Phase D Potassium hydroxide 0.05 Demineralized water 3.00 15 Phase E Cocoa polyphenol 0.10 Crocus sativus extract 5.00 Deionized water 5.00 Phase F Fragrance 0.15 The components of phase A are mixed at approximately 0 ° C, and phase B is added, the components of which are are mixed at 75 ° C, phase C at 70 ° C, phase D at 60 ° C, then phase 10 at 40 ° C, and finally the perfumes are added at 35 ° C, to obtain a lightening cream .
Claims (6)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0801545A FR2928835B1 (en) | 2008-03-20 | 2008-03-20 | DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. |
| PCT/FR2009/000292 WO2009122046A1 (en) | 2008-03-20 | 2009-03-19 | Crocus sativus depigmenting composition |
| EP09729132A EP2282717A1 (en) | 2008-03-20 | 2009-03-19 | Crocus sativus depigmenting composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0801545A FR2928835B1 (en) | 2008-03-20 | 2008-03-20 | DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2928835A1 true FR2928835A1 (en) | 2009-09-25 |
| FR2928835B1 FR2928835B1 (en) | 2010-05-07 |
Family
ID=39884872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0801545A Active FR2928835B1 (en) | 2008-03-20 | 2008-03-20 | DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2282717A1 (en) |
| FR (1) | FR2928835B1 (en) |
| WO (1) | WO2009122046A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012055584A3 (en) * | 2010-10-28 | 2013-03-14 | Henkel Ag & Co. Kgaa | Hair treatment products containing 3-methyl-1,3-butanediol and alkyl polyglycoside(s) |
| FR3001891A1 (en) * | 2013-02-08 | 2014-08-15 | Persiale | Use of a composition comprising an extract of Crocus sativus L., for producing a cosmetic or dermatological composition for treating and preventing degenerative phenomena of skin and for preventing, delaying and/or reducing skin aging |
| FR3032115A1 (en) * | 2015-02-02 | 2016-08-05 | Oreal | COMPOSITION COMPRISING AN ASSOCIATION OF NIOSOMES AND C-GLYCOSIDE DERIVATIVE, CROCUS SATIVUS EXTRACT AND / OR CROCUS SATIVUS FLOWER EXTRACT, FOR REGULATING SKIN PIGMENTATION |
| WO2023198519A1 (en) * | 2022-04-14 | 2023-10-19 | Isp Investments Llc | Crocus sativus flower extracts, compositions comprising same, and uses thereof in oral care |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011144536A1 (en) | 2010-05-18 | 2011-11-24 | Unilever Nv | A personal care composition |
| CN115997927B (en) * | 2022-08-23 | 2024-07-16 | 浙江科技学院 | A buccal tablet containing extracts of stigma croci Sativi and broccoli |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04305519A (en) * | 1991-04-02 | 1992-10-28 | Taisho Pharmaceut Co Ltd | Skin humectant for external use |
| JPH0717845A (en) * | 1993-06-30 | 1995-01-20 | Sansho Seiyaku Co Ltd | Skin external preparation |
| WO2002049580A1 (en) * | 2000-12-20 | 2002-06-27 | Avon Products, Inc. | Compositions and methods for treating hyperpigmentation |
-
2008
- 2008-03-20 FR FR0801545A patent/FR2928835B1/en active Active
-
2009
- 2009-03-19 WO PCT/FR2009/000292 patent/WO2009122046A1/en active Application Filing
- 2009-03-19 EP EP09729132A patent/EP2282717A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04305519A (en) * | 1991-04-02 | 1992-10-28 | Taisho Pharmaceut Co Ltd | Skin humectant for external use |
| JPH0717845A (en) * | 1993-06-30 | 1995-01-20 | Sansho Seiyaku Co Ltd | Skin external preparation |
| WO2002049580A1 (en) * | 2000-12-20 | 2002-06-27 | Avon Products, Inc. | Compositions and methods for treating hyperpigmentation |
Non-Patent Citations (6)
| Title |
|---|
| DATABASE WPI Week 199250, Derwent World Patents Index; AN 1992-410114, XP002502683 * |
| DATABASE WPI Week 199513, Derwent World Patents Index; AN 1995-093749, XP002502682 * |
| KUBO ET AL.: "Flavonols from Saffron Flower: Tyrosinase Inhibitory Activity and Inhibition Mechanism", JOURNAL OF AGRICULTURAL CHEMISTRY, vol. 47, 1999, pages 4121 - 4125, XP002502679 * |
| LI ET AL.: "Antityrosinase Principles and Constituents of the Petals of Crocus sativus", JOURNAL OF NATURAL PRODUCTS, vol. 67, 2004, pages 437 - 440, XP002502678 * |
| LI ET AL.: "Constituents of the Pollen of Crocus sativus L. and Their Tyrosinase Inhibitory Activity", CHEM. PARM. BULL., vol. 50, no. 10, 2002, pages 1305 - 1309, XP002502680 * |
| LI ET AL.: "Constituents of the Stigmas of Crocus sativus and Their Tyrosinase Inhibitory Activity", JOURNAL OF NATURAL PRODUCTS, vol. 65, 2002, pages 1452 - 1456, XP002502681 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012055584A3 (en) * | 2010-10-28 | 2013-03-14 | Henkel Ag & Co. Kgaa | Hair treatment products containing 3-methyl-1,3-butanediol and alkyl polyglycoside(s) |
| FR3001891A1 (en) * | 2013-02-08 | 2014-08-15 | Persiale | Use of a composition comprising an extract of Crocus sativus L., for producing a cosmetic or dermatological composition for treating and preventing degenerative phenomena of skin and for preventing, delaying and/or reducing skin aging |
| FR3032115A1 (en) * | 2015-02-02 | 2016-08-05 | Oreal | COMPOSITION COMPRISING AN ASSOCIATION OF NIOSOMES AND C-GLYCOSIDE DERIVATIVE, CROCUS SATIVUS EXTRACT AND / OR CROCUS SATIVUS FLOWER EXTRACT, FOR REGULATING SKIN PIGMENTATION |
| WO2023198519A1 (en) * | 2022-04-14 | 2023-10-19 | Isp Investments Llc | Crocus sativus flower extracts, compositions comprising same, and uses thereof in oral care |
| FR3134515A1 (en) * | 2022-04-14 | 2023-10-20 | Isp Investments Llc | Crocus sativus flower extracts, compositions comprising them and their uses in oral care |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2282717A1 (en) | 2011-02-16 |
| FR2928835B1 (en) | 2010-05-07 |
| WO2009122046A1 (en) | 2009-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1879602B1 (en) | Use of cacao polyphenols for controlling skin pigmentation | |
| CA2286409C (en) | Cosmetic and/or dermatological compound containing at least one extract of blackberry, at least one extract of skullcap and at least one salicylic acid derivative | |
| FR2928835A1 (en) | DEPIGMENTING COMPOSITION BASED ON CROCUS SATIVUS. | |
| WO2021014057A1 (en) | Cosmetic skin whitening composition comprising hexylresorcinol, undecylenoyl phenylalanine and trimethoxybenzylidene pentanedione | |
| FR2926220A1 (en) | Use of Pancratium maritimum extract as cosmetic antioxidizing agent and/or melanogenesis inhibitor in cosmetic composition e.g. to prevent/fight against the signs of skin aging, and for depigmenting of the skin, body hair and/or hair | |
| EP1877034B1 (en) | Use of cocoa polyphenols for cell cycle regulation in the treatment of hyperkeratinisation | |
| EP1937249B1 (en) | Use of at least one 2-alkyl furan, as depigmenting or lightening active principle | |
| EP3375433B1 (en) | Cosmetic composition comprising a peppermint extract | |
| EP1019017B1 (en) | Association of phenol derivatives with extract of iridaceae family for lightening the skin and superficial body growth and composition containing same | |
| EP2590622B1 (en) | Use of populus balsamifera extract as depigmenting agent | |
| KR101685554B1 (en) | Composition for improving skin containing callus of Broussonetia plant | |
| EP2811978B1 (en) | Use of an apple tree bark extract in a cosmetic anti-ageing composition | |
| EP2811977B1 (en) | Use of an apple tree leaf extract in a cosmetic skin-firming composition | |
| EP2699227A2 (en) | Plant extract complex for skin protection | |
| FR2859102A1 (en) | USE OF A RHODIOLA CRENULATA EXTRACT BY TOPIC | |
| FR2885300A1 (en) | Topical cosmetic and/or dermatological composition useful for skin protection comprises an araucaria seed extract | |
| WO2012136930A2 (en) | Composition of chaulmoogra oil and tribulus terrestris for skin pigmentation | |
| FR3003170A1 (en) | USE OF AN EXTRACT OF WATER JACINTHE FOR MOISTURIZING THE SKIN | |
| FR3076220A1 (en) | ANTELACHE PASTEL OIL | |
| WO2006117464A1 (en) | Skin protective composition based on araucaria grain extracts | |
| FR2885049A1 (en) | Topical cosmetic and/or dermatological composition, useful to protect the skin and to fight against the climatic and environmental effect, comprises a seed extract of Araucaria | |
| JPH0930952A (en) | Dermal preparation for external use | |
| FR2783714A1 (en) | Skin depigmenting composition contains hydroquinone and an alkali metal metabisulfite | |
| FR2986707A1 (en) | COMPOSITION COMPRISING APPLE JUICE EXTRACT FOR SKIN COMFORT. | |
| FR2905861A1 (en) | Use of a Quinoa extract as active ingredient in a composition containing medium, for the preparation of medicament for non-therapeutic treatment of human body to prevent the formation of new fat in the body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property |
Owner name: SOCIETE DE RECHERCHE COSMETIQUE S.A.R.L., LU Effective date: 20140314 |
|
| PLFP | Fee payment |
Year of fee payment: 9 |
|
| PLFP | Fee payment |
Year of fee payment: 10 |
|
| CA | Change of address |
Effective date: 20170223 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |
|
| PLFP | Fee payment |
Year of fee payment: 15 |
|
| PLFP | Fee payment |
Year of fee payment: 16 |
|
| PLFP | Fee payment |
Year of fee payment: 17 |